Further Information
PDE4D, phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila), HGNC:8783, DPDE3, HSPDE4D, PDE4DN2, STRK1, cAMP-specific phosphodiesterase 4D, cAMP-specific phosphodiesterase PDE4D6, dunce-like phosphodiesterase E3, phosphodiesterase 4D, cAMP-specific (dunce (Drosophila)-homolog phosphodiesterase E3), DKFZp686M11213, FLJ97311, phosphodiesterase 4D
Peptide ELISA: antibody detection limit dilution 1:128000.Western Blot:Approx 70+80+90kDa bands observed in lysates of cell line A549. In transfected COS1 transiently expressing PDE4D1 and PDE4D3 bands of approx. 68kDa and 95kDa are observed. These bands are not observed in the untransfected COS1. Calculated MW of 91.1kDa according to PDE4D1 (NP_001098101.1), 76.5kDa according to PDE4D2 (NP_006194.2) and 84.7kDa according to PDE4D3 (NP_001159371.1). Recommended concentration: 0.1-0.3ug/ml.Immunohistochemistry:Paraffin embedded Human Skeletal Muscle and Heart. Recommended concentration: 5ug/ml.ELISA: This antibody has been successfully used in ELISA as described in the following paper: Bazhin et al, Mol Immunol. 2010 Jan;47(4):678-84.; PMID: 19939455.
- Houslay MD. The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target. Mol Pharmacol. 2005 Sep;68(3):563-7.
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Aliquot and store at -20?C. Minimize freezing and thawing.
500 ug/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
The immunogen for this antibody is: QPEACVIDDRSPDT
5144
phosphodiesterase 4D, cAMP-specific
PDE4D
Homo sapiens
Liquid
NP_001184151.1, NP_001184150.1, NP_006194.2, NP_001098101.1, NP_001184152.1, NP_001159371.1
32306513
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Cancer
This antiobody is expected to recognize all reported isoforms.
Q08499